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Abstract	  	  
	  
Researchers	  have	  made	  great	  progress	  in	  understanding	  how	  certain	  
mutations	  in	  DNA	  can	  cause	  normal	  cells	  to	  become	  cancerous.	  	  There	  are	  several	  
theories	  regarding	  reasons	  for	  the	  development	  of	  ovarian	  cancer	  that	  include,	  but	  
not	  limited	  to:	  genetic	  inheritance,	  increasing	  age,	  early	  onset	  of	  menstruation,	  
never	  bearing	  a	  child,	  having	  a	  child	  after	  the	  age	  of	  30,	  and	  no	  previous	  history	  of	  
oral	  contraceptive	  use	  (Royer,	  2002).	  	  There	  is	  insufficient	  evidence	  to	  conclude	  
what	  may	  be	  the	  causative	  factor	  to	  the	  specifics	  in	  the	  development	  of	  ovarian	  
cancer.	  The	  most	  consistently	  reported	  ovarian	  cancer	  risk	  factors	  were	  low	  parity	  
and	  no	  oral	  contraceptive	  use.	  	  Research	  suggests	  that	  a	  correlation	  between	  the	  
total	  number	  of	  menstrual	  cycles	  that	  occur	  throughout	  a	  woman’s	  lifetime	  can	  
directly	  affect	  her	  risk	  of	  developing	  ovarian	  cancer	  (Moorman	  et	  al.,	  2008).	  Using	  
oral	  contraceptives	  decreases	  the	  risk	  of	  developing	  ovarian	  cancer	  by	  reducing	  the	  
total	  number	  of	  times	  a	  woman	  ovulates.	  	  
To	  date,	  there	  are	  currently	  no	  standards	  or	  recommendations	  for	  the	  
screening	  of	  ovarian	  cancer	  in	  asymptomatic	  women,	  making	  educational	  
opportunities	  regarding	  risk	  reduction	  strategies	  a	  priority.	  Oral	  contraceptive	  use,	  
in	  the	  only	  risk	  reduction	  strategy	  available	  for	  the	  prevention	  of	  ovarian	  cancer	  
that	  a	  woman	  is	  able	  to	  initiate	  and	  also	  terminate	  based	  on	  her	  choosing.	  When	  
women	  are	  informed	  that	  increasing	  their	  use	  of	  oral	  contraceptives	  can	  decrease	  
their	  chances	  of	  ovarian	  cancer	  development,	  the	  likelihood	  of	  them	  incorporating	  
these	  protective	  benefits	  will	  be	  increased	  based	  on	  their	  knowledge	  of	  this	  simple	  
prevention	  strategy.	  The	  findings	  that	  follow,	  analyze	  the	  protective	  effects	  of	  oral	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contraceptives	  that	  are	  associated	  with	  reducing	  the	  risk	  of	  ovarian	  cancer	  with	  















































Ovarian	  cancer	  is	  the	  fifth	  leading	  cause	  of	  cancer	  death	  in	  women	  and	  has	  a	  
5-­‐year	  overall	  survival	  rate	  of	  just	  44%	  (Guha,2013).	  	  With	  early	  detection	  methods	  
so	  far	  showing	  no	  benefit	  in	  reducing	  ovarian	  cancer,	  the	  U.S.	  Preventative	  Services	  
Task	  Force	  reaffirmed	  its	  guidance	  against	  routine	  screening	  for	  an	  average	  risk	  
woman.	  	  So	  what	  does	  this	  mean	  in	  terms	  of	  decreasing	  the	  rate	  of	  ovarian	  cancer	  
or	  increasing	  the	  prevention	  of	  ovarian	  cancer?	  Awareness.	  Healthcare	  providers	  
and	  women	  of	  all	  ages	  need	  the	  knowledge	  regarding	  available	  resources	  to	  help	  
decrease	  their	  risk	  of	  ovarian	  cancer	  and	  increase	  prevention	  strategies,	  since	  there	  
are	  no	  current	  screening	  recommendations	  for	  asymptomatic	  women.	  	  Using	  oral	  
contraceptives	  is	  one	  way	  that	  many	  women	  can	  greatly	  reduce	  their	  risk	  of	  
developing	  ovarian	  cancer.	  	  
	   Women	  who	  used	  oral	  contraceptives	  for	  five	  or	  more	  years	  have	  been	  
shown	  to	  have	  almost	  a	  50%	  lower	  risk	  of	  developing	  ovarian	  cancer	  compared	  
with	  women	  who	  never	  used	  oral	  contraceptives	  (Hillard,	  2008).	  With	  these	  
statistics	  existing,	  it	  is	  also	  important	  to	  question,	  how	  does	  oral	  contraceptive	  use	  
compare	  with	  other	  preventable	  measures	  in	  reducing	  ones	  risk	  in	  the	  
development	  of	  ovarian	  cancer?	  The	  data	  in	  the	  following	  sections	  will	  address	  
these	  issues	  and	  provide	  rationale	  regarding	  the	  importance	  of	  oral	  contraceptives	  










Identifying	  Information:	  S.S.	  is	  a	  20	  year	  old	  female	  presenting	  to	  the	  clinic	  today	  to	  
be	  started	  on	  “birth	  control”.	  	  
Chief	  complaint:	  “I	  would	  like	  to	  be	  started	  on	  birth	  control”.	  	  
	  
History	  of	  the	  Present	  Illness:	  	  Pt	  reports	  she	  is	  heterosexual	  and	  has	  had	  a	  history	  
of	  two	  prior	  sexual	  partners,	  both	  male.	  Pt	  denies	  any	  history	  of	  sexually	  
transmitted	  infections	  (STI’s)	  or	  known	  exposures.	  Pt	  denies	  any	  history	  of	  
pregnancy	  or	  abortions,	  but	  did	  use	  an	  emergency	  contraceptive	  “Plan	  B”	  six	  months	  
prior	  without	  any	  noted	  complications.	  Pt	  reports	  occasional	  dysuria	  with	  no	  other	  
symptoms.	  	  
	  
Past	  Medical/Surgical	  History	  
Negative	  
	  	  
Family	  History:	  Pt	  denies	  any	  history	  of	  heart	  disease	  or	  stroke.	  Reports	  father	  had	  a	  
blood	  clot	  after	  surgical	  procedure	  (ankle	  surgery).	  Pt	  denies	  any	  familiar	  history	  of	  
clotting	  disorders	  or	  cancer.	  	  
	  
Personal	  and	  Social	  History:	  Pt	  currently	  a	  sophomore	  at	  the	  University	  of	  North	  
Dakota	  were	  she	  is	  studying	  elementary	  education.	  Pt	  denies	  any	  concerns	  
regarding	  her	  academics.	  Pt	  participates	  in	  moderate	  physical	  activity	  2-­‐3	  times	  per	  
week.	  Denies	  any	  concerns	  about	  her	  current	  weight	  and	  health.	  Pt	  denies	  the	  use	  of	  
recreational	  street	  drugs,	  smoking,	  or	  the	  use	  of	  tobacco	  products.	  Pt	  reports	  
occasional	  alcohol	  use	  of	  2-­‐3	  drinks	  per	  week.	  	  
	  
Medications:	  	  
Xenadrine	  one	  tab	  daily	  	  
Multivitamin	  one	  tab	  daily	  	  
	  
Allergies:	  Penicillin	  	  
	  
Immunizations:	  UTD	  including	  series	  of	  3	  Gardasil	  	  
	  
Review	  of	  Systems	  
HEENT:	  	  Denies	  ear	  and	  eye	  pain.	  Denies	  post	  nasal	  drip,	  sore	  throat	  or	  difficulty	  
swallowing.	  	  
Pulmonary:	  No	  shortness	  of	  breath	  or	  cough.	  	  No	  wheezing	  with	  exertion.	  	  
Cardiovascular:	  Denies	  increasing	  heart	  rate,	  palpitations,	  or	  racing	  heart.	  Denies	  
edema.	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Gastrointestinal:	  Denies	  diarrhea,	  nausea	  or	  vomiting.	  Denies	  change	  in	  appetite	  or	  
recent	  weight	  loss/gain.	  BM	  daily.	  No	  change	  in	  bowel	  habits.	  	  
Endocrine:	  Denies	  fatigue,	  excessive	  thirst,	  and	  changes	  in	  skin	  pigmentation.	  No	  
fever.	  	  
Lymphatic:	  Denies	  bruising	  and	  recent	  blood	  transfusion.	  	  
Mental	  health:	  Denies	  suicidal/homicidal	  ideation.	  Denies	  anxiety	  and	  nervousness.	  	  
Musculoskeletal:	  Denies	  weakness,	  myalgia,	  arthritis,	  or	  recent	  fractures.	  	  
Genitourinary:	  Pt	  denies	  frequency	  or	  hematuria,	  but	  reports	  dysuria	  for	  three	  days.	  	  
Pt	  reports	  yellow	  urine	  with	  no	  vaginal	  discharge	  or	  bleeding.	  No	  foul	  smell	  
noted.	  No	  fever	  or	  suprapubic	  pain	  noted.	  	  
Gynecological:	  Pt	  reports	  regular	  27-­‐28	  day	  cycle,	  with	  mild	  cramping	  noted	  on	  first	  
day	  of	  menses.	  No	  heavy	  bleeding	  noted.	  Pt	  reports	  menarche	  at	  age	  15.	  	  
Neurologic:	  Denies	  headaches,	  dizziness,	  or	  impaired	  speech.	  Denies	  history	  of	  
migraines.	  	  
	  
Physical	  Examination	  	  
General	  Appearance:	  S.S	  is	  a	  20	  year	  old,	  Caucasian	  female	  who	  is	  well-­‐groomed,	  
answered	  questions	  respectfully	  and	  in	  an	  appropriate	  manner.	  
Vital	  signs:	  Height:	  5	  feet	  6	  inches,	  Weight:	  110	  lbs.	  BP:	  122/74,	  HR:	  82,	  
Temperature:	  98.5	  F,	  RR	  16,	  O2	  SAT:	  99%.	  	  
Integumentary:	  Skin	  appropriate	  for	  race.	  Warm	  and	  dry	  to	  touch,	  no	  rashes,	  
nodules	  or	  vesicles	  noted.	  	  
HEENT:	  Head	  is	  normocephalic	  with	  symmetric	  facial	  features.	  	  	  
Eyes:	  Sclera	  white,	  not	  injected.	  Conjunctiva	  pink.	  No	  discharge	  evident.	  Pupils	  
equal.	  	  
Ears:	  No	  pain	  with	  palpation	  to	  auricles,	  pinna,	  or	  mastoid	  process.	  	  
Nose:	  Symmetric,	  no	  discharge	  noted.	  	  	  
Throat	  and	  mouth:	  Lips	  pink	  and	  moist.	  No	  lesions	  noted.	  
Neck:	  	  Symmetric	  without	  masses,	  or	  palpations.	  	  No	  lymphadenopathy,	  
thyromegaly	  or	  thyroid	  nodules.	  	  	  
Chest:	  Chest	  symmetric,	  respirations	  non-­‐labored,	  no	  adventitious	  breath	  sounds.	  	  
Heart:	  normal	  rate,	  regular	  rhythm,	  normal	  S1,	  S2,	  no	  murmurs,	  rubs,	  clicks	  or	  
gallops,	  normal	  rate	  and	  regular	  rhythm	  
Abdomen:	  Normal	  bowel	  sounds	  in	  all	  four	  quadrants.	  Unable	  to	  palpate	  spleen	  or	  
liver.	  	  	  
Musculoskeletal	  system:	  Spine	  straight	  with	  sitting,	  normal	  gait.	  	  No	  costovertebral	  
angle	  tenderness	  over	  bilateral	  kidneys.	  	  
Neurological	  system:	  Alert,	  oriented	  to	  person,	  place	  and	  time.	  	  	  	  
Gynecological:	  Pap	  deferred	  due	  to	  age.	  	  
Plan:	  
1. Patient	  will	  be	  started	  on	  monophasic	  birth	  control.	  Pt	  does	  not	  smoke	  and	  
has	  no	  family	  history	  of	  clotting	  disorders,	  so	  the	  risk	  of	  deep	  vein	  
thrombosis	  and	  pulmonary	  embolism	  is	  low.	  Pt.	  reports	  “I	  don’t	  want	  
anything	  put	  in	  my	  arm	  and	  I	  don’t	  want	  any	  shots”.	  Pt.	  requests	  to	  “take	  a	  
pill	  everyday”.	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2. Pt	  instructed	  that	  she	  may	  experience	  some	  of	  the	  following	  side	  effects,	  all	  of	  
which	  are	  normal	  after	  starting	  an	  oral	  contraceptive.	  	  
a. mild	  weight	  gain	  of	  2-­‐3	  pounds	  	  
b. nausea	  	  
c. breast	  discomfort/and	  or	  enlargement	  	  
d. change	  in	  her	  mood	  	  
e. decreased	  libido	  
f. irregular	  bleeding	  or	  spotting	  
3. Pt.	  instructed	  to	  try	  the	  monophasic	  birth	  control	  for	  three	  months.	  If	  any	  of	  
the	  side	  affects	  are	  not	  tolerable	  to	  call	  the	  office	  and	  discuss	  with	  the	  
provider.	  Pt	  educated	  that	  an	  adequate	  amount	  to	  try	  a	  new	  contraceptive	  is	  
approximately	  three	  months,	  and	  after	  that	  time	  we	  will	  reevaluate	  if	  
symptoms	  warrant	  an	  adjustment	  in	  medication.	  	  
4. Will	  check	  urinalysis	  due	  to	  symptoms	  of	  dysuria.	  	  
5. Will	  check	  urine	  pregnancy.	  
6. Pt	  instructed	  to	  seek	  nearest	  emergency	  department	  if	  she	  experiences	  a	  
sudden	  onset	  of	  shortness	  of	  breath	  or	  heart	  palpitations	  or	  dizziness.	  	  
7. Pt	  verbalized	  that	  she	  is	  not	  concerned	  about	  her	  weight,	  and	  reports	  she	  will	  
stop	  the	  xenadrine	  and	  will	  evaluate	  her	  weight	  in	  three	  months.	  Pt	  will	  
continue	  with	  multivitamin.	  
8. Pt	  encouraged	  to	  continue	  with	  condom	  use	  for	  sexually	  transmitted	  
infection	  prevention.	  	  
9. S.S.	  educated	  regarding	  recent	  data	  that	  has	  been	  studied	  between	  reducing	  
the	  risk	  of	  developing	  ovarian	  cancer	  and	  the	  use	  of	  oral	  contraceptives.	  	  
10. By	  choosing	  the	  oral	  contraceptive	  method,	  S.S	  can	  potentially	  reduce	  her	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   Decades	  of	  data	  show	  that	  oral	  contraceptive	  use	  reduces	  the	  risk	  of	  
developing	  ovarian	  cancer.	  Ovarian	  cancer	  continues	  to	  be	  a	  silent	  killer.	  Most	  
women	  have	  an	  advanced	  disease	  state	  by	  the	  time	  of	  diagnosis.	  Intensive	  efforts	  to	  
develop	  effective	  screening	  strategies	  have	  been	  overturned,	  allowing	  ovarian	  
cancers	  to	  progress	  to	  harmful	  stages	  due	  to	  failed	  efforts	  of	  early	  recognition	  and	  
detection	  screening.	  According	  to	  the	  United	  States	  Preventative	  Services	  Task	  
Force	  (USPSTF)	  Reaffirmation	  Recommendation	  Statement	  “There	  is	  no	  new	  
evidence	  found	  on	  the	  benefits	  of	  screening	  for	  ovarian	  cancer.	  Screening	  
asymptomatic	  women	  can	  result	  in	  unnecessary	  interventions,	  including	  surgery”	  
(Ann	  Family	  Medicine	  2012).	  	  
Why	  are	  these	  current	  recommendations	  alarming?	  Because	  ovarian	  cancer	  
is	  rarely	  found	  in	  its	  early	  stages	  and	  often	  times	  by	  the	  time	  of	  diagnosis	  it	  is	  at	  an	  
advanced	  stage.	  According	  to	  the	  USPSTF,	  ovarian	  cancer	  causes	  more	  deaths	  than	  
any	  other	  cancer	  of	  the	  female	  reproductive	  system	  (Bellcross	  et	  al.,	  2013).	  Ovarian	  
cancer	  has	  few	  symptoms	  warning	  a	  female	  patient	  to	  seek	  treatment	  or	  evaluation	  
making	  the	  prognosis	  grim.	  	  
While	  advances	  in	  surgery,	  chemotherapy,	  and	  radiation	  therapy	  over	  the	  
past	  20	  years	  have	  led	  to	  improved	  outcomes,	  the	  5-­‐year	  survival	  rate	  is	  only	  42	  
percent	  for	  ovarian	  cancer	  compared	  with	  88	  percent	  for	  breast	  cancer	  and	  63	  
percent	  for	  colorectal	  cancer	  as	  reported	  by	  the	  American	  Association	  for	  Cancer	  
Research	  (Epidemiology	  &	  Biomarkers).	  The	  high	  mortality	  rate	  in	  women	  with	  
ovarian	  cancer	  is	  largely	  attributed	  to	  the	  later	  stage	  of	  presentation	  at	  the	  time	  of	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diagnosis	  compared	  with	  other	  common	  cancers.	  This	  has	  led	  to	  intensive	  research	  
efforts	  in	  identify	  effective	  screening	  strategies	  for	  ovarian	  cancer,	  but	  results	  have	  
been	  disappointing,	  due	  to	  the	  lack	  of	  government	  participation	  in	  providing	  
leading	  forefront	  measures	  to	  increase	  protective	  measures	  in	  prevention.	  	  
As	  healthcare	  professionals,	  what	  does	  one	  do	  with	  these	  statistics	  and	  
recommendations?	  The	  best	  answer	  would	  be	  to	  educate	  and	  inform	  health	  care	  
providers	  and	  patients	  of	  the	  protective	  measures	  with	  the	  use	  of	  oral	  
contraceptives	  in	  the	  prevention	  of	  ovarian	  cancer.	  	  Oral	  contraceptive	  use	  has	  
consistently	  been	  found	  to	  be	  associated	  with	  a	  reduced	  risk	  of	  ovarian	  cancer.	  The	  
likelihood	  for	  the	  development	  of	  ovarian	  cancer	  was	  reduced	  with	  longer	  use.	  	  	  The	  
risk	  decreased	  by	  10-­‐12	  percent	  after	  1	  year	  of	  use,	  and	  by	  approximately	  50	  
percent	  after	  5	  years	  of	  use	  (Jatoi	  et	  al.,	  2015).	  	  Because	  there	  are	  no	  current	  
screening	  recommendations,	  it	  is	  important	  to	  participate	  in	  preventative	  measures	  
to	  help	  reduce	  a	  female’s	  risk	  of	  ovarian	  cancer.	  	  
A	  variety	  of	  biological	  explanations	  have	  been	  offered	  regarding	  the	  
protective	  effects	  of	  oral	  contraceptives	  on	  ovarian	  cancer	  risk.	  These	  include:	  (1)	  
excessive	  ovulation	  promotes	  risk;	  (2)	  elevated	  steroid	  hormone	  levels	  increase	  
risk;	  (3)	  unopposed	  estrogen	  increases	  risk;	  and	  (4)	  pelvic	  inflammation	  increases	  
risk	  (Tsilidis	  et	  al.,	  2011).	  Through	  analysis	  of	  the	  data,	  the	  sooner	  a	  female	  is	  
started	  on	  oral	  contraceptives,	  the	  earlier	  one	  may	  receive	  the	  protective	  benefits	  in	  
the	  prevention	  of	  ovarian	  cancer.	  	  
Women	  may	  begin	  to	  ovulate	  in	  their	  teenage	  years	  requiring	  the	  use	  of	  
properly	  functioning	  ovaries	  for	  potentially	  decades.	  With	  the	  use	  of	  oral	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contraceptives	  in	  their	  teenage	  and	  early	  reproductive	  years,	  the	  chances	  for	  the	  
development	  of	  ovarian	  cancer	  in	  woman	  who	  participate	  in	  oral	  contraceptive	  use	  
have	  chosen	  to	  protect	  their	  ovaries	  and	  help	  to	  reduce	  their	  risk	  in	  the	  
development	  of	  ovarian	  cancer	  in	  later	  years.	  	  As	  providers	  who	  deliver	  healthcare,	  
it	  is	  imperative	  that	  the	  discussion	  of	  the	  protective	  benefits	  of	  oral	  contraceptives	  
occurs	  at	  each	  visit	  to	  all	  women	  of	  childbearing	  age.	  	  
Researchers	  have	  studied	  how	  the	  amount	  or	  type	  of	  hormones	  in	  oral	  
contraceptives	  affect	  ones	  ovarian	  cancer	  risk.	  A	  recent	  data	  analysis	  extracted	  from	  
the	  Cancer	  and	  Steroid	  Hormone	  (CASH)	  study	  indicated	  that	  oral	  contraceptive	  
formulations	  with	  higher	  levels	  of	  progestin	  were	  associated	  with	  a	  lower	  risk	  of	  
ovarian	  cancer	  than	  formulations	  with	  low	  progestin	  levels	  The	  change	  of	  a	  higher	  
dose	  of	  the	  progesterone	  component	  within	  the	  oral	  contraceptive	  suggests	  that	  this	  
may	  be	  the	  protective	  mechanism	  in	  preventing	  ovarian	  cancer	  that	  have	  been	  seen	  
with	  the	  estrogen-­‐progestin	  formulations	  of	  oral	  contraceptive	  (Allen,	  2005).	  As	  
deliverers	  of	  healthcare,	  this	  is	  an	  important	  consideration	  to	  remember	  when	  
choosing	  to	  start	  a	  female	  patient	  on	  an	  oral	  contraceptive.	  	  
According	  to	  the	  research	  presented	  by	  Jatoi	  et	  al.,	  (2015)	  the	  approximated	  
risk	  reduction	  for	  the	  development	  of	  ovarian	  cancer	  is	  significant	  among	  women	  
who	  have	  used	  oral	  contraceptives	  for	  10	  years	  or	  longer	  at	  any	  point	  in	  their	  lives.	  
According	  to	  research	  studied	  at	  the	  Mayo	  Clinic	  in	  Rochester,	  Minnesota	  
“Continuous	  ovulation	  is	  thought	  to	  predispose	  to	  ovarian	  epithelial	  cell	  DNA	  
damage,	  which	  in	  turn	  gives	  rise	  to	  carcinogenesis,	  thus	  providing	  mechanistic	  
plausibility	  to	  how	  cessation	  of	  ovulation	  from	  oral	  contraceptives	  might	  lead	  to	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lower	  cancer	  risk”	  (p.137).	  	  Oral	  Contraceptive	  use	  has	  been	  studied	  along	  with	  
several	  proven	  biologically	  plausible	  mechanisms	  for	  their	  protective	  effect,	  which	  
should	  direct	  practitioners	  and	  consumers	  towards	  the	  use	  of	  oral	  contraceptives	  
for	  the	  prevention	  of	  ovarian	  cancer.	  	  
More	  than	  23,000	  cases	  of	  ovarian	  cancer	  are	  diagnosed	  in	  the	  Unites	  States	  
annually,	  with	  a	  median	  age	  at	  diagnosis	  of	  63	  years.	  	  Although	  more	  than	  two	  thirds	  
of	  ovarian	  cancer	  cases	  are	  diagnosed	  among	  postmenopausal	  women,	  most	  known	  
risk	  factors	  are	  characteristics	  related	  to	  reproduction	  that	  occur	  primarily	  when	  
women	  are	  in	  their	  twenties	  and	  thirties	  (Havrilesky,	  2013).	  The	  choices	  that	  a	  
female	  patient	  makes	  in	  her	  20s	  and	  30s	  may	  have	  a	  lasting	  and	  overall	  protective	  
effect	  on	  reducing	  her	  chances	  of	  developing	  ovarian	  cancer	  in	  her	  later	  years.	  	  	  	  
Within	  this	  literature	  review	  it	  is	  evident	  that	  oral	  contraceptive	  use	  has	  
been	  proven	  effective	  for	  the	  risk	  reduction	  of	  ovarian	  cancer,	  which	  makes	  it	  also	  
important	  to	  compare	  oral	  contraceptive	  use	  with	  other	  preventable	  measures	  and	  
modifiable	  risk	  factors	  in	  prevention.	  	  If	  a	  genetic	  history	  is	  common	  among	  a	  family,	  
a	  woman	  may	  choose	  to	  continue	  with	  genetic	  testing	  to	  determine	  her	  likelihood	  of	  
being	  a	  carrier	  of	  the	  BRCA	  gene.	  This	  gene	  is	  known	  to	  be	  genetically	  linked	  to	  an	  
increased	  chance	  of	  developing	  ovarian	  cancer	  (Robinson,	  2015).	  So	  far,	  what	  is	  
known	  about	  risk	  factors	  has	  not	  translated	  into	  practical	  ways	  to	  prevent	  most	  
cases	  of	  ovarian	  cancer.	  Both	  tubal	  ligation	  and	  hysterectomy	  with	  oophorectomy	  
may	  reduce	  the	  chance	  of	  developing	  ovarian	  cancer	  in	  carriers	  of	  the	  BRCA	  gene,	  
but	  experts	  agree	  that	  these	  operations	  should	  only	  be	  done	  for	  medical	  reasons-­‐	  
not	  for	  their	  effect	  on	  ovarian	  cancer	  prevention	  (Menkiszak,	  2016).	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A	  large	  European	  studied	  examined	  reproductive	  variables	  in	  the	  
development	  of	  ovarian	  cancer.	  	  The	  examination	  consisted	  of	  an	  analysis	  of	  woman	  
who	  conceived	  a	  child	  compared	  with	  those	  who	  did	  not.	  Women	  who	  had	  given	  
birth	  (parity)	  had	  a	  29%	  lower	  risk	  of	  ovarian	  cancer	  with	  a	  progressive	  reduction	  
in	  risk	  with	  each	  additional	  pregnancy.	  	  This	  study	  confirms	  the	  strong	  protective	  
association	  of	  oral	  contraceptive	  use	  and	  parity	  in	  reducing	  the	  risk	  of	  ovarian	  
cancer.	  No	  other	  significant	  associations	  with	  risk	  reduction	  were	  found	  for	  age	  at	  
menarche,	  age	  at	  first	  full-­‐term	  pregnancy,	  incomplete	  pregnancies	  or	  breastfeeding	  
(Tsilidis,	  2011).	  Although	  there	  is	  no	  proven	  way	  that	  one	  can	  completely	  prevent	  
this	  disease;	  one	  is	  clearly	  able	  to	  lower	  their	  risk	  of	  developing	  ovarian	  cancer	  
through	  the	  use	  of	  oral	  contraceptives	  and	  an	  increasing	  number	  of	  times	  a	  female	  
conceives	  a	  child.	  The	  seemingly	  obvious	  factor	  that	  a	  woman	  is	  able	  to	  control	  and	  
actively	  regulate	  is	  oral	  contraceptive	  use.	  It	  seems	  to	  have	  the	  strongest	  correlation	  
with	  risk	  reduction	  in	  ovarian	  cancer,	  and	  although	  child	  bearing	  does	  lessen	  your	  
chance	  of	  developing	  ovarian	  cancer,	  this	  risk	  reduction	  factor	  is	  not	  always	  ideal	  
for	  all	  women.	  	  
Many	  women	  worry	  about	  oral	  contraceptives	  increasing	  their	  risk	  of	  other	  
cancers.	  According	  to	  Bui	  and	  associates	  “For	  women	  who	  are	  pre-­‐menopausal	  and	  
normally	  would	  have	  estrogen	  and	  progesterone	  in	  their	  system,	  taking	  the	  birth	  
control	  pill	  does	  not	  increase	  the	  risk	  of	  breast	  cancer.	  For	  post-­‐menopausal	  women,	  
long-­‐term	  use	  of	  hormones,	  especially	  combining	  estrogen	  and	  progesterone	  can	  
slightly	  increase	  the	  risk	  of	  developing	  breast	  cancer,	  but	  not	  the	  risk	  of	  dying	  from	  
breast	  cancer”	  (p.230).	  With	  these	  statistics	  present,	  reassurance	  and	  misconception	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regarding	  the	  topics	  of	  increasing	  other	  types	  of	  cancer	  with	  oral	  contraceptives	  
should	  be	  discussed	  with	  each	  patient.	  The	  benefits	  and	  risk	  reduction	  of	  the	  
prevention	  of	  ovarian	  cancer	  out	  weigh	  the	  risks	  and	  have	  proven	  to	  be	  beneficial	  in	  
lessening	  ones	  chance	  of	  ovarian	  cancer,	  due	  to	  the	  lack	  of	  preventive	  testing	  being	  
reinforced.	  	  
Several	  of	  the	  health	  benefits	  and	  risks	  associated	  with	  the	  oral	  contraceptive	  
pill	  are	  particularly	  relevant	  to	  women	  at	  risk	  of	  ovarian	  cancer.	  In	  a	  recent	  study	  
published	  regarding	  women’s	  beliefs	  on	  oral	  contraceptives,	  Fifty-­‐three	  percent	  of	  
women	  had	  positive	  attitudes	  towards	  oral	  contraceptives.	  Most	  women	  felt	  
confident	  with	  their	  use	  in	  consuming	  oral	  contraceptives	  and	  felt	  this	  may	  have	  the	  
largest	  predictability	  in	  reducing	  their	  cancer	  risks	  (Crane,	  2011).	  	  
As	  healthcare	  providers,	  the	  mission	  should	  be	  to	  educate	  and	  inform	  women	  
of	  their	  risk	  factors	  for	  the	  development	  of	  ovarian	  cancer	  and	  preventative	  
measures	  that	  can	  reduce	  their	  lifetime	  risk	  of	  ovarian	  cancer	  which	  include	  the	  use	  
of	  oral	  contraceptives.	  	  Through	  a	  combined	  effort	  of	  education	  and	  implemented	  
prevention	  strategies	  from	  healthcare	  providers	  to	  female	  patients,	  the	  likelihood	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Learning	  Points	  
• Ovarian	  cancer	  continues	  to	  be	  a	  silent	  killer	  of	  women.	  Most	  women	  have	  an	  
advanced	  disease	  at	  the	  time	  of	  their	  diagnosis	  due	  to	  a	  lack	  of	  screening	  
measures	  and	  prevention	  strategies.	  The	  protective	  effects	  of	  oral	  
contraceptive	  pills	  have	  been	  well	  documented	  and	  studied,	  and	  their	  use	  
should	  be	  encouraged	  to	  help	  decrease	  ones	  risk	  of	  ovarian	  cancer.	  	  
• The	  most	  consistently	  reported	  ovarian	  cancer	  risk	  factors	  are	  nulliparity,	  
low	  parity	  and	  no	  oral	  contraceptive	  use.	  	  With	  these	  factors	  in	  mind,	  
education	  regarding	  oral	  contraceptive	  use	  should	  begin	  in	  early	  
reproductive	  years	  as	  the	  choices	  that	  a	  female	  makes	  during	  this	  time	  can	  
supply	  protective	  effects	  from	  the	  development	  of	  ovarian	  cancer	  well	  into	  a	  
woman’s	  later	  years.	  	  
• The	  research	  reviewed	  not	  only	  supported	  preventative	  measures	  in	  
reducing	  ovarian	  cancer	  rates,	  it	  favored	  an	  association	  between	  prior	  oral	  
contraceptive	  use	  and	  an	  improved	  overall	  survival	  rate	  among	  those	  women	  
diagnosed	  with	  ovarian	  cancer	  at	  a	  later	  age.	  	  
• A	  greater	  than	  20%	  relative	  risk	  reduction	  appears	  to	  occur	  for	  every	  5	  years	  
a	  woman	  reports	  taking	  oral	  contraceptives.	  This	  risk	  reduction	  for	  the	  
development	  of	  ovarian	  cancer	  is	  significant	  among	  women	  who	  have	  used	  
oral	  contraceptives	  for	  10	  years	  or	  longer	  at	  any	  point	  in	  their	  lives.	  
• Oral	  contraceptives	  represent	  a	  promising	  primary	  prevention	  strategy	  for	  
ovarian	  cancer	  and	  healthcare	  providers	  should	  encourage	  their	  use	  as	  
ovarian	  cancers	  progress	  rapidly,	  due	  to	  a	  lack	  of	  early	  detection	  screening	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and	  their	  protective	  benefits	  should	  be	  brought	  to	  the	  attentions	  of	  all	  female	  
patients.	  The	  change	  of	  a	  higher	  dose	  of	  the	  progesterone	  component	  within	  
the	  oral	  contraceptive	  suggests	  that	  this	  may	  be	  the	  protective	  mechanism	  in	  
preventing	  ovarian	  cancer	  that	  have	  been	  seen	  with	  the	  estrogen-­‐progestin	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